1.Subendocardial Ischemic Necrosis in Hypertrophied Rabbit Heart Induced by Chronic Aoric.
Sung Sook KIM ; Dong Sun HAN ; Ie Tae PARK
Korean Circulation Journal 1997;27(7):738-743
BACKGROUND: Cardiac hypertrophy is the compensatory response of the myocadium to increased workload. Compensatory mechanisms come into play when the hypertrophied heart can no longer accommodate the increased demand or persistent stimuli. Although it has been reported that the molecular changes in hypertrophied hearts that initially mediate enhanced function may contribute to the development of heart failure, the structural/biochemical/molecular basis for myocardial contractile failure is still obscure. This study was aimed to clarify the structural basis for relation between hypertrophy and failure. METHOD: Nine pairs of rabbits were sacrificed at 8,12,24,48 hours and 1,2,4,6,8 weeks after experiment aortic constriction. There hearts were studied with routine histopathology. Each heart was weighed and compared with total body weight. Multiple sections were embedded in paraffin, sectioned at 5um, and stained with hematoxylin and cosin and Masson's trichrome and analysed. RESULTS: The heart weight to body weight ratio(g/Kg) increased progressively with time after aortic banding. Banding of the aorta in the rabbit resulted in multifocal areas of myofiber degeneration, necrosis and fibrosis through the wall of the left ventricle, in the papillary muscles of the left ventricle and in the left ventricular portions of the interventricular septum in rabbit of 6 and 8 weeks after aortic banding. By 4 weeks after banding, the foci of necrosis were not observed. CONCLUSION: There findings suggest that the increased necrosis, fibrosis in animals with cardiac hypertrophy induced by banding the aorta may play a role in progression to heart failure.
Animals
;
Aorta
;
Body Weight
;
Cardiomegaly
;
Constriction
;
Fibrosis
;
Heart Failure
;
Heart Ventricles
;
Heart*
;
Hematoxylin
;
Hypertrophy
;
Necrosis*
;
Papillary Muscles
;
Paraffin
;
Rabbits
2.Porocarcinoma Arising in a Ganglion Cyst: A Case Report and Review of the Literature.
Ie Hyon PARK ; Tae Hoon KIM ; Sung Tack KWON ; Ji Ung PARK
Archives of Reconstructive Microsurgery 2016;25(2):56-59
Eccrine porocarcinoma is a rare malignant neoplasm of the eccrine sweat gland that often occurs in the lower extremities, and usually affects elderly individuals. Most cases of eccrine porocarcinoma arise de novo. We encountered a case of a large porocarcinoma arising in a pre-existing ganglion cyst in the knee. The malignant tumor was excised widely, and the defect was reconstructed using a free anterolateral thigh flap.
Aged
;
Eccrine Porocarcinoma
;
Ganglion Cysts*
;
Humans
;
Knee
;
Lower Extremity
;
Sweat Glands
;
Thigh
3.Two Cases of Primary Sclerosing Cholangitis.
Chang Hong LEE ; Jae Seon KIM ; Young Tae BAK ; Jin Ho KIM ; Jong Guk KIM ; Kwan Soo BYUN ; Jong Eun YEON ; Kyoung Min KIM ; Ie Byung PARK
Korean Journal of Gastrointestinal Endoscopy 1995;15(4):788-795
Prirnary sclerosing cholangitis, a chronic progressive cholestatic hepatobiliary disorder of unknown etiology, is characterized by inflammation, scarring and obliteration of bile duct leading to biliary cirrhosis and liver failure. Because histologic finding has only a limited role in the diagnosis, the gold standard for establishing the diagnosis is cholangiographic demonstration of typical diffuse biliary stricutre or beading. The natural history is extremely variable. We report two cases of primary sclerosing cholangitis diagnosed by repeated endoscopic retrograde cholangiographies. They were followed up for 7 and 2 years, respectively.
Bile Ducts
;
Cholangiography
;
Cholangitis, Sclerosing*
;
Cicatrix
;
Diagnosis
;
Inflammation
;
Liver Cirrhosis, Biliary
;
Liver Failure
;
Natural History
4.A Clinicopathologic Study of 31 Cases with Ovarian Malignant Germ Cell Tumors.
Nam Won SEO ; Cheon Jun LEE ; Do Hyung KIM ; Un Mo AHN ; Tae Hong YEO ; Jun Houg KIM ; Sunn Ie AHN ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 2000;43(1):51-57
OBJECTIVE: The purpose of this study was to review the clinicopathologic features, recurrent rate, survival rate and controversable issues in the treatment of the ovarian malignant germ cell tumors. PATIENTS AND METHODS: From August, 1991 to November, 1998 thirty-one patients with malignant germ cell tumors of the ovary treated in the department of obstetrics and gynecology, Kosin University Medical college, were eligible and assessable. Demographic characteristics, symptoms, signs, stage, tumor grade, mode of therapy and results of follow up were reviewed retrospectively. RESULTS: The patients with malignant germ cell tumor constituted 6.37% of all ovarian malignancies during this period. Histologic subtypes were 8 dysgerminoma(25.8%), 7 endodermal sinus tumor(22.6%), 10 immature teratoma(32.3%), 3 mixed germ cell tumor(9.7%), 3 choriocarcinoma(9.7%). The age of the patients ranged from 10 to 40 years (mean +/-S.D.; 24.26 +/- 7.51). The most common symptom was abdominal pain(38.7%). Most had stageI(18 cases, 58.0%) or stageIII(5 cases, 16.2%) diseases. All patients underwent surgery as the initial treatment, and nine patients received more than one operation. Postoperative adjuvant chemotherapeutic regimens were VAC, VBP, EP, BEP, EMA, and EMA CO. The mean follow up duration was 26.0(+/- S.D.; +/- 20.3) months. The 2-year and 5-year survival rate were 91.97%(+/- S.E.; +/- 0.05) and 86.86%(+/- S.E.; +/- 0.07).
Endoderm
;
Female
;
Follow-Up Studies
;
Germ Cells*
;
Gynecology
;
Humans
;
Neoplasms, Germ Cell and Embryonal*
;
Obstetrics
;
Ovary
;
Retrospective Studies
;
Survival Rate
5.Acquired Palatal Fistula in Patients with Submucous and Incomplete Cleft Palate before Surgery.
Ie Hyon PARK ; Jee Hyeok CHUNG ; Tae Hyun CHOI ; Jihyeon HAN ; Suk Wha KIM
Archives of Plastic Surgery 2016;43(6):582-585
It is uncommon for a palatal fistula to be detected in individuals who have not undergone surgery, and only sporadic cases have been reported. It is even more difficult to find cases of acquired palatal fistula in patients with submucous or incomplete cleft palate. Herein, we present 2 rare cases of this phenomenon. Case 1 was a patient with submucous cleft palate who acquired a palatal fistula after suffering from oral candidiasis at the age of 5 months. Case 2 was a patient with incomplete cleft palate who spontaneously, without trauma or infection, presented with a palatal fistula at the age of 9 months.
Candidiasis, Oral
;
Cleft Palate*
;
Fistula*
;
Humans
;
Oral Fistula
6.Body Fat Is Related to Sedentary Behavior and Light Physical Activity but Not to Moderate-Vigorous Physical Activity in Type 2 Diabetes Mellitus
Keun Hee AN ; Kyung Ah HAN ; Tae Seo SOHN ; Ie Byung PARK ; Hae Jin KIM ; Sung Dae MOON ; Kyung Wan MIN
Diabetes & Metabolism Journal 2020;44(2):316-325
Background:
Sedentary behavior (SB) has emerged as a new risk factor for cardiovascular accidents. We investigated whether physical activity levels or SB were related to percent body fat (%BF) in type 2 diabetes mellitus (T2DM).
Methods:
In this cross sectional study, we measured the duration of SB, light physical activity (LPA), moderate to vigorous physical activity (MVPA), total energy expenditure, and step counts using a wireless activity tracker (Fitbit HR; FB) for 7 days in freeliving conditions, along with %BF using a bio impedance analyzer (Inbody; Biospace) in 120 smartphone users with T2DM. Subjects were divided into exercise (Exe, n=68) and non-exercise (nonExe, n=52) groups based on self-reports of whether the recommended exercises (30 min/day, 3 days/week for 3 months) were performed. SBt, LPAt, MVPAt were transformed from SB, LPA, MVPA for normally distributed variables.
Results:
Participants were: female, 59.2%; age, 59.3±8.4 years; body mass index, 25.5±3.4 kg/m2; glycosylated hemoglobin (HbA1c), 7.6%±1.2%; %BF, 30.4%±7.1%. They performed SB for 15.7±3.7 hr/day, LPA for 4.4±1.7 hr/day, and MVPA for 0.9±0.8 hr/day. The %BF was related to SBt and LPAt, but not to MVPA after adjustments for age, gender, and HbA1c. VPA was significantly higher in the Exe group than in the nonExe group, but SB, LPA, and moderate physical activity were not different. Predicted %BF was 89.494 to 0.105 (age), –13.047 (gender), –0.507 (HbA1c), –7.655 (LPAt) (F[4, 64]=62.929, P<0.001), with an R2 of 0.785 in multiple linear regression analysis.
Conclusion
Reduced body fat in elderly diabetic patients might be associated with reduced inactivity and increased LPA.
7.Dectection of Ureaplasma urealyticum in Invasive Cervical Cancer Tissue.
Un Mo AHN ; Nam Won SEO ; Do Hyung KIM ; Tae Hong YEO ; Tae Kyoung KANG ; Jun Hong KIM ; Sunn Ie AHN ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 2001;44(4):663-667
OBJECTIVE: Mycoplasmas have been implicated in many diseases including cervicitis, urethritis, salpingitis, endometritis... and functioning as cofactors catalyzing the HIV disease state. The oncogenic potentiality of mycoplasma was only recently realized when they were shown causing chromosomal changes and in vitro cell transformations through gradual progressive chromsomal loss and translocation. Few study has been reported the prevalence of mycoplasma infection in human cancers and suggested that there was a connection between these organisms and human cancers. The objective of this study was to determine the relationship between Ureaplasma urealyticum infection and cervical cancer. METHODS: The detection frequency of Ureaplasma urealyticum in 52 invasive cervical cancer tissues and 17 normal cervical tissues was studied using PCR. RESULTS: U. urealyticum DNA was detected in 8 out of 52(15.4%) invasive cervical cancer tissues and 1 out of 17(5.9%) normal cervical tissues. No statistic significance was observed between the detection frequency of Ureaplasma urealyticum and clinicopathologic parameters. The prevalence of Ureaplasma urealyticum in invasive cervical tissues was 15.4% and this rate was higher than 5.9% in normal cervical tissues but there was no statistic significance. CONCLUSIONS: With respect to clinicopathologic parameters of cervical cancer, there was no significant relation between U. urealyticum infection and cervical cancer. There is, however, few study and case on cervical cancer internally and externally. It is considered that more studies on the subject with much cases should be made.
Carcinogenesis
;
DNA
;
Endometritis
;
Female
;
HIV
;
Humans
;
Mycoplasma
;
Mycoplasma Infections
;
Polymerase Chain Reaction
;
Prevalence
;
Salpingitis
;
Ureaplasma urealyticum*
;
Ureaplasma*
;
Urethritis
;
Uterine Cervical Neoplasms*
;
Uterine Cervicitis
8.Expression of MAGE 3 Gene Products in Uterine Cervical Carcinoma.
Tae Kyoung KANG ; Nam Won SEO ; Do Hyung KIM ; Un Mo AHN ; Tae Hong YEO ; Jun Hong KIM ; Sunn Ie AHN ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 2001;44(3):519-524
OBJECTIVE: The human MAGE 3 gene encodes tumor specific antigens that are recognized by autologue cytotoxic T lymphocytes (CTL). The MAGE 3 gene is expressed not only in melanoma but in the other malignant tumors as well. There is, however, little information on the expression of the gene in uterine cervical carcinomas. The author thus studied the expression of the MAGE 3 gene products in uterine cervical carcinoma and discuss the possibility of specific immunologic diagnosis using MAGE 3 gene products. METHODS: The expression of MAGE 3 gene product in 17 normal tissues of the cervix, 32 cervical intraepithelial neoplasia (8 CIN I, 10 CIN II, 14 CIS), and 43 invasive cervical carcinomas was studied by immunohistochemistry using anti-MAGE 3 mAb 57B in paraffin sections RESULTS: No expression of MAGE 3 gene product was detected in normal cervical tissues and in cervical intraepithelial neoplasias. The expression of MAGE 3 gene product was detected in 30.2% (13/43) of invasive cervical carcinomas. The MAGE 3 gene product was stained as a cytoplasmic protein in cancer cells. No statistically significant differences were observed between MAGE 3 gene product expression status and clinicopathologic parameters. CONCLUSIONS: The MAGE 3 gene products was expressed in invasive cervical carcinoma tissues.
Cervical Intraepithelial Neoplasia
;
Cervix Uteri
;
Cytoplasm
;
Female
;
Humans
;
Immunohistochemistry
;
Immunologic Tests
;
Melanoma
;
Paraffin
;
T-Lymphocytes, Cytotoxic
9.Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study.
Jeong Il KIM ; Seok Hyun KIM ; Byung Seok LEE ; Heon Young LEE ; Tae Hee LEE ; Young Woo KANG ; Hyang Ie LEE ; An Na KIM ; Soon Woo NAM ; Byeong Chool PARK ; Hee Bok CHAE ; Seok Bae KIM ; Il Han SONG ; Ji Young PARK ; Hong Su KIM
The Korean Journal of Hepatology 2008;14(4):493-502
BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. METHODS: Ninety-seven patients were treated with peginterferon alpha-2a (180 microgram/week, n=48) or peginterferon alpha-2b (1.5 microgram/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. RESULTS: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. CONCLUSIONS: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
Adult
;
Antiviral Agents/*administration & dosage
;
Combined Modality Therapy
;
Genotype
;
Hepacivirus/drug effects/genetics
;
Hepatitis C, Chronic/diagnosis/*drug therapy
;
Humans
;
Interferon Alfa-2a/*administration & dosage
;
Interferon Alfa-2b/*administration & dosage
;
Korea
;
Middle Aged
;
Polyethylene Glycols/*administration & dosage
;
Retrospective Studies
;
Ribavirin/*administration & dosage
;
Risk Factors
10.γ-Linolenic Acid versus α-Lipoic Acid for Treating PainfulDiabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, NoninferiorityTrial
Jong Chul WON ; Hyuk-Sang KWON ; Seong-Su MOON ; Sung Wan CHUN ; Chong Hwa KIM ; Ie Byung PARK ; In Joo KIM ; Jihyun LEE ; Bong Yun CHA ; Tae Sun PARK
Diabetes & Metabolism Journal 2020;44(4):542-554
This study was a multicenter, parallel-group, double-blind, double-dummy, randomized,noninferiority trial to evaluate the efficacy and safety of γ-linolenic acid(GLA) relative to α-lipoic acid (ALA) over a 12-week treatment period in type 2diabetes mellitus (T2DM) patients with painful diabetic peripheral neuropathy (DPN). This study included 100 T2DM patients between 20 and 75 years of age who had painfulDPN and received either GLA (320 mg/day) and placebo or ALA (600 mg/day) and placebo for12 weeks. The primary outcome measures were mean changes in pain intensities as measuredby the visual analogue scale (VAS) and the total symptom scores (TSS). Of the 100 subjects who initially participated in the study, 73 completed the 12-weektreatment period. Per-protocol analyses revealed significant decreases in the mean VASand TSS scores compared to baseline in both groups, but there were no significantdifferences between the groups. The treatment difference for the VAS (95% confidenceinterval [CI]) between the two groups was −0.65 (−1.526 to 0.213) and theupper bound of the 95% CI did not exceed the predefined noninferiority margin(δ1=0.51). For the TSS, the treatment difference was −0.05(−1.211 to 1.101) but the upper bound of the 95% CI crossed the noninferioritymargin (δ2=0.054). There were no serious adverse events associatedwith the treatments. GLA treatment in patients with painful DPN was noninferior to ALA in terms of reducingpain intensity measured by the VAS over 12 weeks.